お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
997615

アンチトロンビンの世界市場

Antithrombin

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 221 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.20円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

アンチトロンビンの世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 221 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のアンチトロンビンの市場規模は、分析期間(2020年~2027年)に4.9%のCAGRで成長する見通しで、2020年の4億8,620万米ドルから、2027年には6億8,100万米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つである治療薬は、分析期間中に5%のCAGRで成長し、6億4,010万米ドルに達すると予測されています。

当レポートは、世界のアンチトロンビン市場について調査しており、市場シェア、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • CSL Behring
  • Grifols International SA
  • Kedrion SpA
  • Lee Biosolutions, Inc.
  • LFB SA
  • Scripps Laboratories
  • Shire PLC

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と推進要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • 企業プロファイル:41社
目次
Product Code: MCP16149

Abstract:

Global Antithrombin Market to Reach $681 Million by 2027

Amid the COVID-19 crisis, the global market for Antithrombin estimated at US$486.2 Million in the year 2020, is projected to reach a revised size of US$681 Million by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027. Therapeutics, one of the segments analyzed in the report, is projected to record a 5% CAGR and reach US$640.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Research segment is readjusted to a revised 3.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $143.3 Million, While China is Forecast to Grow at 4.7% CAGR

The Antithrombin market in the U.S. is estimated at US$143.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$120.7 Million by the year 2027 trailing a CAGR of 4.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Diagnostics Segment to Record 4.1% CAGR

In the global Diagnostics segment, USA, Canada, Japan, China and Europe will drive the 4.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$11.1 Million in the year 2020 will reach a projected size of US$14.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$76.1 Million by the year 2027.

Select Competitors (Total 41 Featured) -

  • CSL Behring
  • Grifols International SA
  • Kedrion SpA
  • Lee Biosolutions, Inc.
  • LFB SA
  • Scripps Laboratories
  • Shire PLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Antithrombin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Antithrombin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Antithrombin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Goat Milk by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Goat Milk by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Goat Milk by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Lyophilized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Lyophilized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Lyophilized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Liquid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Liquid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Liquid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 28: USA Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 31: USA Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: USA 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 34: USA Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 37: Canada Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Canada 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 40: Canada Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 46: Japan Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Japan Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Japan 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 49: Japan Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Japan 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 52: Japan Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Japan Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Japan 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 55: China Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: China 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 58: China Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: China Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: China 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 61: China Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: China 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 64: Europe Current & Future Analysis for Antithrombin by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 65: Europe Historic Review for Antithrombin by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Europe 15-Year Perspective for Antithrombin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 67: Europe Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Europe 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 70: Europe Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Europe 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 73: Europe Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Europe Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Europe 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 76: France Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: France Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: France 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 79: France Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: France Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: France 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 82: France Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: France Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: France 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 85: Germany Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Germany Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Germany 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 88: Germany Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Germany Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Germany 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 91: Germany Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Germany Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Germany 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 94: Italy Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Italy Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Italy 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 97: Italy Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Italy Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Italy 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 100: Italy Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Italy Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Italy 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 103: UK Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: UK Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: UK 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 106: UK Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: UK Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: UK 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 109: UK Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: UK Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: UK 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 112: Rest of Europe Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Rest of Europe Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: Rest of Europe 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 115: Rest of Europe Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Rest of Europe Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: Rest of Europe 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 118: Rest of Europe Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Rest of Europe Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: Rest of Europe 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 121: Asia-Pacific Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Asia-Pacific Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Asia-Pacific 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 124: Asia-Pacific Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Asia-Pacific Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Asia-Pacific 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 127: Asia-Pacific Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Asia-Pacific Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Asia-Pacific 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 130: Rest of World Current & Future Analysis for Antithrombin by Application - Therapeutics, Research and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Rest of World Historic Review for Antithrombin by Application - Therapeutics, Research and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Rest of World 15-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics, Research and Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 133: Rest of World Current & Future Analysis for Antithrombin by Source - Human, Goat Milk and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Rest of World Historic Review for Antithrombin by Source - Human, Goat Milk and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Rest of World 15-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human, Goat Milk and Other Sources for the Years 2012, 2020 & 2027
    • TABLE 136: Rest of World Current & Future Analysis for Antithrombin by Dosage Form - Lyophilized and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Rest of World Historic Review for Antithrombin by Dosage Form - Lyophilized and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Rest of World 15-Year Perspective for Antithrombin by Dosage Form - Percentage Breakdown of Value Sales for Lyophilized and Liquid for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 41
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.